ZT006 / Beijing QL Biopharma - LARVOL DELTA

Efficacy and Safety of ZT006 in Overweight and Obese Participants (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

New P2 trial • Genetic Disorders • Obesity

ZT006, a novel oral GLP-1 receptor agonist improves memory function, reduces brain insulin resistance and neuroinflammation in Alzheimer's disease animal models (EASD 2025) - "In AD animal models, ZT006 delayed the cognitive decline and prevented key neurodegenerative changes, possibly mediated by reducing brain insulin resistance and neuroinflammation. These data suggested that ZT006 tablet represents a novel treatment strategy for AD."

Late-breaking abstract • Preclinical • Metabolic Disorders • Obesity • IL1B • IL6 • TNFA

Treatment of Alzheimer's disease - The third indication of the innovative oral GLP-1 peptide of Peptide Biopeptide was approved for clinical trials [Google translation] (bydrug.pharmcube.com) - "On March 31, 2025, the oral GLP-1 peptide ZT006 tablets independently developed by Beijing Zhipeptide Biopharmaceutical Technology Co., Ltd. obtained the implicit clinical trial approval of the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the treatment of Alzheimer's disease."

New trial • Alzheimer's Disease